This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings
by Sweta Killa
We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.
Bet on Defensive Sector ETFs as Stimulus Talks Stall
by Sweta Killa
The halt in stimulus talks has made investors jittery, resulting in a flight to defensive sectors like utilities, real estate, healthcare and consumer staples.
Trump vs. Biden First Presidential Debate: ETFs in Focus
by Sweta Killa
After months of campaign, President Donald Trump and Democratic nominee Joe Biden will come face-to-face on debate stage on Sep 30 in Cleveland.
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
UnitedHealth Beats: Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported stronger-than-expected second-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.
Q2 Earnings Likely To Plunge: Invest in These Sector ETFs
by Sweta Killa
Earnings growth is expected to be negative for 15 of the 16 Zacks sectors with double-digit declines.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests
by Sweta Jaiswal, FRM
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
Healthcare ETFs in Focus Post UnitedHealth's Q1 Earnings
by Sweta Killa
UnitedHealth reported mixed first-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged the same for revenues.
JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus
by Sweta Killa
Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.
Any Bright Spot in Q1 Earnings? Sector ETFs & Stocks to Buy
by Sweta Killa
First-quarter results are likely to be bleak, given that the coronavirus outbreak are weighing on corporate profits. However, there are still some bright spots. Let's have a look.
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Healthcare ETFs in Focus on UnitedHealth's Q4 Earnings
by Sweta Killa
UnitedHealth Group reported mixed fourth-quarter 2019 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged on revenues.
Deal or No Deal: Healthcare ETFs to Make a Sweep in 2020
by Sanghamitra Saha
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Healthcare ETFs to Buy on UnitedHealth's Solid Q3 Earnings
by Sweta Killa
Investors could tap the company's strong growth story with ETFs having the largest allocation to this health insurance giant.
JNJ Beats, Ups View: Healthcare ETFs to Buy
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Healthcare ETFs in Focus on UnitedHealth's Q2 Earnings
by Sweta Killa
ETFs having the largest allocation to this health insurance giant are in focus post Q2 earnings.
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
by Sweta Killa
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Forget Trade Fears, Invest in Defensive Sector ETFs
by Sweta Killa
Investors are seeking to beat the fresh tariff woes by betting on defensive sectors like utilities, real estate, healthcare and consumer staples. We have highlighted one ETF each from these four zones.
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
UnitedHealth Falls Despite Q1 Beat, Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported robust first-quarter 2019 results. The company breezed past the Zacks Consensus Estimate on both earnings and revenues and raised its full-year forecast.